<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02132247</url>
  </required_header>
  <id_info>
    <org_study_id>08US/Fp03</org_study_id>
    <nct_id>NCT02132247</nct_id>
  </id_info>
  <brief_title>Safety Study of Flector Patch in Children With Minor Soft Tissue Injuries</brief_title>
  <official_title>An Open-label, Prospective, Uncontrolled Study of the Safety and Local Tolerability of the Diclofenac Epolamine Patch (Flector Patch) in Pediatric Patients With Minor Soft Tissue Injuries</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IBSA Institut Biochimique SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IBSA Institut Biochimique SA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to determine whether Flector Patch is safe for use in
      children. The secondary purpose is to assess blood levels of diclofenac, the active
      ingredient in Flector Patch.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2014</start_date>
  <completion_date type="Actual">May 2017</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dermatologic Assessment at the Patch Application Site</measure>
    <time_frame>Up to 2 weeks, depending upon pain resolution</time_frame>
    <description>None - 0; Faint redness - 1; Moderate redness - 2; Intense redness - 3; Redness with edema or papules - 4; Redness with weeping vesicles, blisters or bullae - 5; Redness with extension of effect beyond margin of contact site - 6.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Investigator Assessment of the Global Response to Therapy on a 5-point Scale</measure>
    <time_frame>Up to 2 weeks, depending upon pain resolution</time_frame>
    <description>5-point scale: No clinical improvement in pain intensity and/or functional performance - 1; Slight clinical improvement in pain intensity and/or functional performance - 2; Moderate clinical improvement in pain intensity and/or functional performance - 3; Marked clinical improvement in pain intensity and/or functional performance - 4; Restoration of normal functional performance in the absence of any pain - 5.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Assessment of Pain on a 6-point Scale</measure>
    <time_frame>Up to 2 weeks, depending upon pain resolution</time_frame>
    <description>Wong-Baker FACES Scale 6-point scale:
No Hurt - 0; Hurts Little Bit - 1; Hurts Little More - 2; Hurts Even More - 3; Hurts Whole Lot - 4; Hurts Worst - 5.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration of Diclofenac</measure>
    <time_frame>Day 2 and either Day 4, 7 or 14, depending upon pain resolution</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">104</enrollment>
  <condition>Athletic Injuries</condition>
  <arm_group>
    <arm_group_label>Flector Patch</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Flector Patch is a transdermal delivery system containing 180 mg of diclofenac hydroxyethylpyrrolidine. The patch will be used twice-a-day for up to two weeks, or until pain resolution, whichever comes first.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diclofenac hydroxyethylpyrrolidine</intervention_name>
    <arm_group_label>Flector Patch</arm_group_label>
    <other_name>Flector Patch</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 6 to 16 years, either gender

          -  Informed consent: 6-9 year olds must have their parent/legally authorized
             representative complete a Parental Permission Form; 10-16 year olds must complete a
             Children's Assent Form and have their parent/legally authorized representative
             complete a Parental Permission Form

          -  Minor soft tissue injury within 96 hours of study entry

          -  Spontaneous pain of at least moderate intensity (i.e. pain of at least 3 on the
             6-point Wong- Baker Faces scale for pain severity assessment by patient)

          -  Injury must be considered by the Investigator to be clinically significant

          -  Negative urine pregnancy test at screening for female subjects of childbearing
             potential (started the menstrual cycle)

          -  Able to read and speak English

          -  Available with their parents for the immediate two week period following study
             enrollment

        Exclusion Criteria:

          -  Major soft tissue injury (Fractures are only exclusionary if the injury is stabilized
             with a device, e.g. a hard cast, that cannot be removed to allow a patch to be applied
             to the site of injury)

          -  Open skin lesion or any dermatological condition (e.g. skin infection, eczema) within
             the injured area

          -  Injury is midline or involves the spine, digits or hands

          -  Prior injury to the same site within the past 3 months

          -  Three or more other prior injuries (minor or major) to the region in the past

          -  Injury occurred more than 96 hours prior to study entry

          -  Prior use of topical medication to involved area within 48 hours of study entry

          -  Allergic disorders, including asthma or urticaria, but only if associated with
             exposure to aspirin or an NSAID

          -  Coagulation defects

          -  Prior use of over-the-counter (OTC) analgesics or short-acting non-steroidal
             anti-inflammatory drugs (NSAIDs [ibuprofen, ketoprofen]) within 6 hours of study entry
             (acetaminophen permitted up until the time of study entry)

          -  Prior use of narcotic analgesics within 7 days of study entry

          -  Prior use of systemic anti-inflammatory steroidal drugs within 60 days of study entry

          -  Prior use of long-acting NSAIDs such as piroxicam or naproxen since injury

          -  Concomitant use of drugs which may be susceptible to interactions with diclofenac, or
             affect safety if used concomitantly (serotonin-selective reuptake inhibitors (SSRI),
             lithium, digoxin, anticoagulants, antidiabetic agents, cyclosporin, methotrexate,
             quinolone antimicrobials, other NSAIDs, steroids and diuretics)

          -  Subjects suffering from psychiatric disorders (including depression)

          -  Handicapped patients, but only if the handicap prevents them from either assessing
             their pain or safely using the patch (e.g., pervasive developmental disorders such as
             autism, Asperger syndrome, Rett syndrome, Heller's syndrome, severe attention deficit
             hyperactivity disorders (ADHD), other severe mental retardation of traumatic,
             congenital or other origin)

          -  History of current alcohol or drug abuse dated &lt; 1 year

          -  Severe cardiac, renal or hepatic impairment

          -  Severe systemic diseases (e.g. cancer, severe acute infection)

          -  Any underlying disease or medication that severely compromise the patient's immune
             system

          -  Prior history of any chronic pain disorder

          -  Prior history of GI bleeds/ulcers, liver or kidney disease

          -  Hypersensitivity to diclofenac or other NSAID drugs (including aspirin)

          -  Females who are pregnant or breast feeding

          -  Patients participating or having been involved in other clinical investigations during
             the three months preceding the entry of this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clarence Jones, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>IBSA Institut Biochimique SA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Applied Research Center of Arkansas</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SCORE Physician Alliance</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatrics and Adolescent Medicine P.A.</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30062</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arlington Family Research Center Inc.</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Utah Valley Pediatrics</name>
      <address>
        <city>Orem</city>
        <state>Utah</state>
        <zip>84057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>J. Lewis Research Inc./Foothill Family Clininc</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>J. Lewis Research Inc./FirstMed East</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>J. Lewis Research Inc./Foothill Family Clinic South</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Legacy Point Family Medicine</name>
      <address>
        <city>West Point</city>
        <state>Utah</state>
        <zip>84015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatric Research of Charlottesville</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 28, 2014</study_first_submitted>
  <study_first_submitted_qc>May 5, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2014</study_first_posted>
  <results_first_submitted>March 6, 2018</results_first_submitted>
  <results_first_submitted_qc>April 9, 2018</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 10, 2018</results_first_posted>
  <last_update_submitted>April 9, 2018</last_update_submitted>
  <last_update_submitted_qc>April 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Minor athletic injuries</keyword>
  <keyword>Pain</keyword>
  <keyword>Diclofenac</keyword>
  <keyword>Topical</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Soft Tissue Injuries</mesh_term>
    <mesh_term>Athletic Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diclofenac</mesh_term>
    <mesh_term>Diclofenac hydroxyethylpyrrolidine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>There were no significant events in the study between enrollment (i.e. determination of eligibility) and assignment to the Flector Patch arm.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Flector Patch/Age 6-11</title>
          <description>Flector Patch is a topical delivery system containing 180 mg of diclofenac epolamine. The patch will be used twice-a-day for up to two weeks, or until pain resolution, whichever comes first.</description>
        </group>
        <group group_id="P2">
          <title>Flector Patch/Age 12-16</title>
          <description>Flector Patch is a topical delivery system containing 180 mg of diclofenac epolamine. The patch will be used twice-a-day for up to two weeks, or until pain resolution, whichever comes first.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Flector Patch/Age 6-11</title>
          <description>6-11 year old participants treated with Flector Patch twice per day.</description>
        </group>
        <group group_id="B2">
          <title>Flector Patch/Age 12-16</title>
          <description>12-16 year old participants treated with Flector Patch twice per day.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="52"/>
            <count group_id="B2" value="52"/>
            <count group_id="B3" value="104"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <description>Eligible patients between 6 and 16 years old were enrolled in equal numbers into two subgroups, 6-11 years old and 12-16 years old.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="85"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Injury-Associated Pain Assessment</title>
          <description>Wong-Baker FACES Scale: No Hurt - 0; Hurts little bit - 1; Hurts little more - 2; Hurts even more - 3; Hurts whole lot - 4; Hurts worst - 5</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.37" spread=".56"/>
                    <measurement group_id="B2" value="3.58" spread="0.64"/>
                    <measurement group_id="B3" value="3.47" spread="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>Inches</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.1" spread="4.8"/>
                    <measurement group_id="B2" value="66.4" spread="3.5"/>
                    <measurement group_id="B3" value="60.2" spread="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>Pounds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80.3" spread="28.1"/>
                    <measurement group_id="B2" value="149.0" spread="43.6"/>
                    <measurement group_id="B3" value="114.7" spread="50.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Dermatologic Assessment at the Patch Application Site</title>
        <description>None - 0; Faint redness - 1; Moderate redness - 2; Intense redness - 3; Redness with edema or papules - 4; Redness with weeping vesicles, blisters or bullae - 5; Redness with extension of effect beyond margin of contact site - 6.</description>
        <time_frame>Up to 2 weeks, depending upon pain resolution</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Flector Patch/Age 6-11</title>
            <description>6-11 year old participants treated with Flector Patch twice per day.</description>
          </group>
          <group group_id="O2">
            <title>Flector Patch/Age 12-16</title>
            <description>12-16 year old participants treated with Flector Patch twice per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Dermatologic Assessment at the Patch Application Site</title>
          <description>None - 0; Faint redness - 1; Moderate redness - 2; Intense redness - 3; Redness with edema or papules - 4; Redness with weeping vesicles, blisters or bullae - 5; Redness with extension of effect beyond margin of contact site - 6.</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day1-2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.10" spread="0.30"/>
                    <measurement group_id="O2" value="0.04" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.20"/>
                    <measurement group_id="O2" value="0.06" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5-7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" spread="0.32"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8-11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="0.06" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 12-15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Investigator Assessment of the Global Response to Therapy on a 5-point Scale</title>
        <description>5-point scale: No clinical improvement in pain intensity and/or functional performance - 1; Slight clinical improvement in pain intensity and/or functional performance - 2; Moderate clinical improvement in pain intensity and/or functional performance - 3; Marked clinical improvement in pain intensity and/or functional performance - 4; Restoration of normal functional performance in the absence of any pain - 5.</description>
        <time_frame>Up to 2 weeks, depending upon pain resolution</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Flector Patch/Age 6-11</title>
            <description>6-11 year old participants treated with Flector Patch twice per day.</description>
          </group>
          <group group_id="O2">
            <title>Flector Patch/Age 12-16</title>
            <description>12-16 year old participants treated with Flector Patch twice per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Investigator Assessment of the Global Response to Therapy on a 5-point Scale</title>
          <description>5-point scale: No clinical improvement in pain intensity and/or functional performance - 1; Slight clinical improvement in pain intensity and/or functional performance - 2; Moderate clinical improvement in pain intensity and/or functional performance - 3; Marked clinical improvement in pain intensity and/or functional performance - 4; Restoration of normal functional performance in the absence of any pain - 5.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No clinical improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slight clinical improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate clinical improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Marked clinical improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normal function with no pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Assessment of Pain on a 6-point Scale</title>
        <description>Wong-Baker FACES Scale 6-point scale:
No Hurt - 0; Hurts Little Bit - 1; Hurts Little More - 2; Hurts Even More - 3; Hurts Whole Lot - 4; Hurts Worst - 5.</description>
        <time_frame>Up to 2 weeks, depending upon pain resolution</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Flector Patch/Age 6-11</title>
            <description>6-11 year old participants treated with Flector Patch twice per day.</description>
          </group>
          <group group_id="O2">
            <title>Flector Patch/Age 12-16</title>
            <description>12-16 year old participants treated with Flector Patch twice per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Assessment of Pain on a 6-point Scale</title>
          <description>Wong-Baker FACES Scale 6-point scale:
No Hurt - 0; Hurts Little Bit - 1; Hurts Little More - 2; Hurts Even More - 3; Hurts Whole Lot - 4; Hurts Worst - 5.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.37" spread="0.56"/>
                    <measurement group_id="O2" value="3.58" spread="0.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12" spread="0.47"/>
                    <measurement group_id="O2" value="0.27" spread="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentration of Diclofenac</title>
        <time_frame>Day 2 and either Day 4, 7 or 14, depending upon pain resolution</time_frame>
        <population>One participant missed a blood draw.</population>
        <group_list>
          <group group_id="O1">
            <title>Flector Patch/Age 6-11</title>
            <description>6-11 year old participants treated with Flector Patch twice per day.</description>
          </group>
          <group group_id="O2">
            <title>Flector Patch/Age 12-16</title>
            <description>12-16 year old participants treated with Flector Patch twice per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentration of Diclofenac</title>
          <population>One participant missed a blood draw.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>24-hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.83" spread="2.10"/>
                    <measurement group_id="O2" value="1.46" spread="1.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.49" spread="3.01"/>
                    <measurement group_id="O2" value="1.11" spread="1.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected for 2 years and 5 months.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Flector Patch/Age 6-11</title>
          <description>6-11 year old participants treated with Flector Patch twice per day.</description>
        </group>
        <group group_id="E2">
          <title>Flector Patch/Age 12-16</title>
          <description>12-16 year old participants treated with Flector Patch twice per day.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="52"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Christopher Jones, Ph.D.</name_or_title>
      <organization>IBSA Pharma Inc.</organization>
      <phone>(202) 753-6475 ext 7005</phone>
      <email>chris.jones@ibsapharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

